MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Veru EBITDA 2011-2026 | VERU
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Veru
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -36.6 M | -93.5 M | -37.3 M | 13.1 M | -184 K | -5.96 M | -20.4 M | -7.08 M | 4.92 M | 7.11 M | 4.51 M | 10.3 M | 11.4 M | 3.76 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 M | -93.5 M | -10.4 M |
Quarterly EBITDA Veru
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.4 M | - | -7.52 M | -8.09 M | -10.2 M | - | -10.5 M | -8.86 M | -7.32 M | - | -13.7 M | -34.4 M | -37.4 M | -38.5 M | -21.8 M | -11.7 M | -4.94 M | 14.9 M | -2.85 M | -1.45 M | 19.2 M | -3.24 M | -1.31 M | 19.2 M | -1.71 M | -4.75 M | -1.77 M | -1.71 M | -969 K | -16.9 M | -4.9 M | -934 K | -7.39 M | -5.45 M | -1.09 M | -7.39 M | -1.79 M | 3.64 M | 1.08 M | -1.79 M | 2.51 M | 6.23 M | 1.71 M | 2.51 M | 1.58 M | 4.84 M | 2.31 M | 1.58 M | 1.73 M | 8.47 M | 1.36 M | 1.73 M | 3.73 M | 8.1 M | 3.03 M | 3.73 M | 2.9 M | 1.34 M | 684 K | 2.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 M | -38.5 M | -2.92 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Drug manufacturers industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
-19.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
6.82 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-176 M | $ 2.67 | 3.49 % | $ 1.37 B |  Canada |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-23.6 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-40 M | - | - | $ 754 M | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81.6 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
306 M | - | - | $ 28.9 M |  Irlanda |
 |
Catalent
CTLT
|
-260 M | - | - | $ 11.5 B | USA |
 |
Harrow Health
HROW
|
31.8 M | $ 40.53 | 0.72 % | $ 1.49 B | USA |
 |
Athenex
ATNX
|
-65.5 M | - | -23.39 % | $ 1.76 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
3.06 M | $ 4.19 | -0.48 % | $ 58.9 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-39.7 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
654 K | - | - | $ 33.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Bausch Health Companies
BHC
|
2.23 B | $ 5.72 | 2.33 % | $ 2.09 B | Canada |
 |
Canopy Growth Corporation
CGC
|
-95.6 M | $ 1.11 | 1.83 % | $ 119 M | Canada |
 |
Lannett Company
LCI
|
-142 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.41 | 2.92 % | $ 402 M | Canada |
 |
Evolus
EOLS
|
-25.2 M | $ 5.39 | 4.05 % | $ 347 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.36 | 3.42 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-601 M | $ 8.23 | 3.0 % | $ 421 M | USA |
 |
Organogenesis Holdings
ORGO
|
12.3 M | $ 2.35 | 2.17 % | $ 309 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-100 M | - | - | $ 193 M | Canada |
 |
Pacira BioSciences
PCRX
|
5.41 M | $ 25.49 | 1.39 % | $ 1.18 B | USA |
 |
ProPhase Labs
PRPH
|
28.3 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-53.2 M | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
8.47 M | $ 18.43 | 2.11 % | $ 118 M | USA |
 |
PetIQ
PETQ
|
81.6 M | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
-178 M | $ 7.26 | 2.98 % | $ 635 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.57 M | $ 1.1 | 3.77 % | $ 1.37 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.52 | 2.04 % | $ 297 M | USA |
 |
Recro Pharma
REPH
|
4.65 M | - | -4.76 % | $ 65.3 M | USA |
 |
Tilray
TLRY
|
-1.37 B | $ 6.24 | 1.63 % | $ 3.86 B | Canada |
 |
OptiNose
OPTN
|
-22.3 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.93 | -0.46 % | $ 46.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
3.51 B | $ 14.94 | -0.2 % | $ 17.9 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.44 | 4.56 % | $ 86.3 M | Canada |
 |
cbdMD
YCBD
|
-2.86 M | $ 0.87 | 0.15 % | $ 3.75 M | USA |
 |
Zomedica Corp.
ZOM
|
-82.3 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-2.5 M | $ 0.88 | -2.56 % | $ 31.7 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-1.74 M | $ 0.54 | -1.78 % | $ 2.32 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.01 M | $ 2.04 | -3.32 % | $ 23.6 M | USA |